Rainer Puhr
YOU?
Author Swipe
View article: Transforming Clinical Trials in Skin Cancer Research: Exploring the Potential of Flexible and Innovative Designs
Transforming Clinical Trials in Skin Cancer Research: Exploring the Potential of Flexible and Innovative Designs Open
View article: A fast, flexible simulation framework for Bayesian adaptive designs -- the R package BATSS
A fast, flexible simulation framework for Bayesian adaptive designs -- the R package BATSS Open
The use of Bayesian adaptive designs for randomised controlled trials has been hindered by the lack of software readily available to statisticians. We have developed a new software package (Bayesian Adaptive Trials Simulator Software - BAT…
View article: Supplementary Table S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (HER2+ cohort)
View article: Supplementary Figure S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Selected CpG sites covering the genomic locus of HER3 (ERBB3) were evaluated for their methylation state (A).
View article: Supplementary Table S5 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S5 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (TNBC cohort)
View article: Supplementary Figure S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Further evaluation of HER3 expression in BM of breast and lung cancer.
View article: Supplementary Table S6 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S6 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Pathway enrichment analysis of genes associated with differentially methylated CpG sites in HER3+ vs. HER3-
View article: Supplementary Figure S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Selected CpG sites covering the genomic locus of HER3 (ERBB3) were evaluated for their methylation state (A).
View article: Supplementary Table S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Baseline characteristics of patients used for genome-wide DNA-methlyation analysis, stratified into HER3-positive and HER3-negative
View article: Supplementary Figure S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Further evaluation of HER3 expression in BM of breast and lung cancer.
View article: Supplementary Figure S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Immune cell infiltration in BM of the three subtypes of BCa: Luminal (A), HER2-positive (B) and Triple-negative breast cancer (TNBC) (C).
View article: Supplementary Table S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (HER2+ cohort)
View article: Supplementary Table S6 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S6 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Pathway enrichment analysis of genes associated with differentially methylated CpG sites in HER3+ vs. HER3-
View article: Supplementary Table S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Protocols used for IHC stainings on the Ventana Benchmark ULTRA device
View article: Supplementary Table S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Protocols used for IHC stainings on the Ventana Benchmark ULTRA device
View article: Supplementary Table S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Baseline characteristics of patients used for genome-wide DNA-methlyation analysis, stratified into HER3-positive and HER3-negative
View article: Supplementary Figure S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Kaplan-Meier curves of patients with BM of A) Luminal-BCa B) HER2+ BCa C) TN-BCa, and D) NSCLC patients stratified according to the intensity of HER3 expression determined by IHC.
View article: Supplementary Table S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (Luminal cohort)
View article: Supplementary Figure S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Immune cell infiltration in BM of the three subtypes of BCa: Luminal (A), HER2-positive (B) and Triple-negative breast cancer (TNBC) (C).
View article: Supplementary Table S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (Luminal cohort)
View article: Supplementary Figure S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Kaplan-Meier curves of patients with BM of A) Luminal-BCa B) HER2+ BCa C) TN-BCa, and D) NSCLC patients stratified according to the intensity of HER3 expression determined by IHC.
View article: Supplementary Table S5 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S5 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (TNBC cohort)
View article: Data from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Data from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Purpose: HER3 belongs to a family of receptor tyrosine kinases with oncogenic properties and is targeted by a variety of novel anticancer agents. There is a huge unmet medical need for systemic treatment options in patients with brain meta…
View article: Prognosticators of survival in patients with metastatic pancreatic cancer and ascites
Prognosticators of survival in patients with metastatic pancreatic cancer and ascites Open
View article: Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer Open
Baseline characteristics of patients used for genome-wide DNA-methlyation analysis, stratified into HER3-positive and HER3-negative
View article: Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (TNBC cohort)
View article: Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer Open
Baseline characteristics of patients used for genome-wide DNA-methlyation analysis, stratified into HER3-positive and HER3-negative
View article: Supplementary Figure S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Supplementary Figure S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer Open
Kaplan-Meier curves of patients with BM of A) Luminal-BCa B) HER2+ BCa C) TN-BCa, and D) NSCLC patients stratified according to the intensity of HER3 expression determined by IHC.
View article: Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (Luminal cohort)
View article: Supplementary Figure S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Supplementary Figure S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer Open
Further evaluation of HER3 expression in BM of breast and lung cancer.